Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...

Celebrities have sent prostate cancer’s public profile soaring in recent years. But with accusations that some men are being ...

Pancreatic cancer often hides in plain sight. Many of its earliest warnings look like everyday problems. A stubborn bout of indigestion, or a new backache that will not settle. A strange change in ...

A trial of the new device, described as a potential "game-changer" for the disease, is to be carried out by researchers in ...

Professor Prabhakar Rajan has spoken out about the concerning rate of prostate cancer diagnoses and the one thing he wants men to do to tackle it ...

Tests and screenings exist that help doctors detect these illnesses and take potentially life-saving action before the ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

A leading doctor in the fight against prostate cancer has shared what every man should know about the disease. Professor ...